An assessment of different filter systems for extracorporeal elimination of bivalirudin: an in vitro study.
Bivalirudin is a new, direct thrombin inhibitor. We investigated the extracorporeal elimination rate of different hemofilters and one plasmapheresis filter for bivalirudin. Our data show that bivalirudin can be effectively eliminated via hemofiltration and plasmapheresis, although there were significant differences in the elimination rates among the filter systems investigated.
Koster
Andreas
A
Departments for *Anesthesia and †Thoracic and Cardiovascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ‡Department of Cardiology, Flinders Medical Center, South Australia, Australia; and §Department of Cardiothoracic Anesthesia, Virginia Commonwealth University, Richmond, Virginia.
Chew
Derek
D
Gründel
Marcus
M
Hausmann
Harald
H
Grauhan
Onnen
O
Kuppe
Herman
H
Spiess
Bruce D
BD
D000925:Anticoagulants / Q000302:isolation & purification*; D001774:Blood Chemical Analysis; D002315:Cardiopulmonary Bypass; D006400:Hematocrit; D006440:Hemofiltration / Q000379:methods*; D006629:Hirudins / Q000031:analogs & derivatives* / Q000302:isolation & purification*; D006801:Humans; D066298:In Vitro Techniques; D009997:Osmotic Pressure; D010446:Peptide Fragments / Q000302:isolation & purification*; D011994:Recombinant Proteins / Q000302:isolation & purification*; D006435:Renal Dialysis; D014462:Ultrafiltration
D000925:Anticoagulants; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; C074619:bivalirudin